1.48
+0.01(+0.68%)
Currency In USD
Address
245 Hammersmith Road
London, W6 8PW
United Kingdom of Great Britain and Northern Ireland
Phone
44 20 8154 4600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
204
First IPO Date
March 31, 2021
| Name | Title | Pay | Year Born |
| Dr. Iraj Ali Ph.D. | Chief Executive Officer | 1.7M | 1975 |
| Mr. Daniel Carey Cazel Hood | General Counsel, Company Secretary & Director | 0 | N/A |
| Mr. Tariq Ahmed | Executive Vice President of People | 0 | N/A |
| Dr. Sergio A. Quezada Ph.D. | Founder | 0 | 1976 |
| Dr. Charles Swanton FMEDSCI, M.D., Ph.D. | Founder & Member of Scientific Advisory Board | 0 | 1972 |
| Mr. Lee M. Stern | Vice President of Investor Relations & External Communications | 0 | N/A |
| Julia Wilson | Head of Communications | 0 | N/A |
| Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. | Founder & Member of Scientific Advisory Board | 0 | 1963 |
| Mr. Robert Coutts | Chief Financial Officer & Director | 0 | 1984 |
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.